402 related articles for article (PubMed ID: 19700662)
1. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation.
Leen AM; Christin A; Myers GD; Liu H; Cruz CR; Hanley PJ; Kennedy-Nasser AA; Leung KS; Gee AP; Krance RA; Brenner MK; Heslop HE; Rooney CM; Bollard CM
Blood; 2009 Nov; 114(19):4283-92. PubMed ID: 19700662
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus (EBV) load in bone marrow transplant recipients at risk to develop posttransplant lymphoproliferative disease: prophylactic infusion of EBV-specific cytotoxic T cells.
Gustafsson A; Levitsky V; Zou JZ; Frisan T; Dalianis T; Ljungman P; Ringden O; Winiarski J; Ernberg I; Masucci MG
Blood; 2000 Feb; 95(3):807-14. PubMed ID: 10648390
[TBL] [Abstract][Full Text] [Related]
3. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs.
Gottschalk S; Ng CY; Perez M; Smith CA; Sample C; Brenner MK; Heslop HE; Rooney CM
Blood; 2001 Feb; 97(4):835-43. PubMed ID: 11159505
[TBL] [Abstract][Full Text] [Related]
4. Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.
Qian C; Campidelli A; Wang Y; Cai H; Venard V; Jeulin H; Dalle JH; Pochon C; D'aveni M; Bruno B; Paillard C; Vigouroux S; Jubert C; Ceballos P; Marie-Cardine A; Galambrun C; Cholle C; Clerc Urmes I; Petitpain N; De Carvalho Bittencourt M; Decot V; Reppel L; Salmon A; Clement L; Bensoussan D
J Hematol Oncol; 2017 May; 10(1):102. PubMed ID: 28482908
[TBL] [Abstract][Full Text] [Related]
5. A phase I-II trial to examine the toxicity of CMV- and EBV-specific cytotoxic T lymphocytes when used for prophylaxis against EBV and CMV disease in recipients of CD34-selected/T cell-depleted stem cell transplants.
Lucas KG; Sun Q; Burton RL; Tilden A; Vaughan WP; Carabasi M; Salzman D; Ship A
Hum Gene Ther; 2000 Jul; 11(10):1453-63. PubMed ID: 10910142
[TBL] [Abstract][Full Text] [Related]
6. Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation.
Doubrovina E; Oflaz-Sozmen B; Prockop SE; Kernan NA; Abramson S; Teruya-Feldstein J; Hedvat C; Chou JF; Heller G; Barker JN; Boulad F; Castro-Malaspina H; George D; Jakubowski A; Koehne G; Papadopoulos EB; Scaradavou A; Small TN; Khalaf R; Young JW; O'Reilly RJ
Blood; 2012 Mar; 119(11):2644-56. PubMed ID: 22138512
[TBL] [Abstract][Full Text] [Related]
7. Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease.
Vickers MA; Wilkie GM; Robinson N; Rivera N; Haque T; Crawford DH; Barry J; Fraser N; Turner DM; Robertson V; Dyer P; Flanagan P; Newlands HR; Campbell J; Turner ML
Br J Haematol; 2014 Nov; 167(3):402-10. PubMed ID: 25066775
[TBL] [Abstract][Full Text] [Related]
8. Antigenic competition in the generation of multi-virus-specific cell lines for immunotherapy of human cytomegalovirus, polyomavirus BK, Epstein-Barr virus and adenovirus infection in haematopoietic stem cell transplant recipients.
Roubalová K; Němečková Š; Kryštofová J; Hainz P; Pumannová M; Hamšíková E
Immunol Lett; 2020 Dec; 228():64-69. PubMed ID: 33031870
[TBL] [Abstract][Full Text] [Related]
9. T cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant.
Comoli P; Basso S; Labirio M; Baldanti F; Maccario R; Locatelli F
Blood Cells Mol Dis; 2008; 40(1):68-70. PubMed ID: 17904879
[TBL] [Abstract][Full Text] [Related]
10. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomas.
Liu Z; Savoldo B; Huls H; Lopez T; Gee A; Wilson J; Brenner MK; Heslop HE; Rooney CM
Recent Results Cancer Res; 2002; 159():123-33. PubMed ID: 11785836
[TBL] [Abstract][Full Text] [Related]
11. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies.
Gottschalk S; Edwards OL; Sili U; Huls MH; Goltsova T; Davis AR; Heslop HE; Rooney CM
Blood; 2003 Mar; 101(5):1905-12. PubMed ID: 12411306
[TBL] [Abstract][Full Text] [Related]
12. Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease.
Lucas KG; Salzman D; Garcia A; Sun Q
Cancer; 2004 May; 100(9):1892-901. PubMed ID: 15112270
[TBL] [Abstract][Full Text] [Related]
13. Strategies of adoptive T -cell transfer to treat refractory viral infections post allogeneic stem cell transplantation.
Kaeuferle T; Krauss R; Blaeschke F; Willier S; Feuchtinger T
J Hematol Oncol; 2019 Feb; 12(1):13. PubMed ID: 30728058
[TBL] [Abstract][Full Text] [Related]
14. First-in-man clinical results with good manufacturing practice (GMP)-compliant polypeptide-expanded adenovirus-specific T cells after haploidentical hematopoietic stem cell transplantation.
Geyeregger R; Freimüller C; Stemberger J; Artwohl M; Witt V; Lion T; Fischer G; Lawitschka A; Ritter J; Hummel M; Holter W; Fritsch G; Matthes-Martin S
J Immunother; 2014 May; 37(4):245-9. PubMed ID: 24714358
[TBL] [Abstract][Full Text] [Related]
15. Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients.
Rooney CM; Smith CA; Ng CY; Loftin SK; Sixbey JW; Gan Y; Srivastava DK; Bowman LC; Krance RA; Brenner MK; Heslop HE
Blood; 1998 Sep; 92(5):1549-55. PubMed ID: 9716582
[TBL] [Abstract][Full Text] [Related]
16. [Monitoring of early Epstein-Barr virus reactivation and preemptive therapy after allogeneic hematopoietic stem cell transplantation].
Lu Y; Wu T; Cao XY; Wang JB; Sun Y; Zhao YL; DA WM; Ji SQ; Tong CR; Lu DP
Zhonghua Nei Ke Za Zhi; 2011 May; 50(5):383-7. PubMed ID: 21624219
[TBL] [Abstract][Full Text] [Related]
17. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation.
Comoli P; Basso S; Zecca M; Pagliara D; Baldanti F; Bernardo ME; Barberi W; Moretta A; Labirio M; Paulli M; Furione M; Maccario R; Locatelli F
Am J Transplant; 2007 Jun; 7(6):1648-55. PubMed ID: 17511690
[TBL] [Abstract][Full Text] [Related]
18. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant.
Gerdemann U; Katari UL; Papadopoulou A; Keirnan JM; Craddock JA; Liu H; Martinez CA; Kennedy-Nasser A; Leung KS; Gottschalk SM; Krance RA; Brenner MK; Rooney CM; Heslop HE; Leen AM
Mol Ther; 2013 Nov; 21(11):2113-21. PubMed ID: 23783429
[TBL] [Abstract][Full Text] [Related]
19. Adoptive transfer of epstein-barr virus (EBV) nuclear antigen 1-specific t cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation.
Icheva V; Kayser S; Wolff D; Tuve S; Kyzirakos C; Bethge W; Greil J; Albert MH; Schwinger W; Nathrath M; Schumm M; Stevanovic S; Handgretinger R; Lang P; Feuchtinger T
J Clin Oncol; 2013 Jan; 31(1):39-48. PubMed ID: 23169501
[TBL] [Abstract][Full Text] [Related]
20. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]